Template:Available forms of testosterone
Jump to navigation
Jump to search
Route | Ingredient | Form | Dose | Frequency | Major brand names |
---|---|---|---|---|---|
Oral | Testosterone undecanoate | Capsule | 40 mg | 2–4x per day | Andriol, Andriol Testocaps, Jatenzo |
Sublingual | Testosterone | Tablet | 10 mg | 1–4x per day | Testoral |
Buccal | Testosterone | Tablet | 30 mg | 2x per day | Striant |
Intranasal | Testosterone | Nasal gel | 5.5 mg per spray (120 sprays per bottle) | 3x per day | Natesto |
Transdermal | Testosterone | Non-scrotal patch | 2.5, 4, 5, or 6 mg T per day | 1x every 1–2 days | Androderm, AndroPatch, TestoPatch |
Non-scrotal patch | 150 or 300 μg T per day | 1x every 3–4 days | Intrinsa | ||
Scrotal patch | 4 or 6 mg T per day | 1x per day | Testoderm | ||
Topical gel (1–2.5%) | 25, 50, 75, 100, or 125 mg T per application | 1x per day | AndroGel, Testim, TestoGel | ||
Axillary solution (2%) | 30 mg T per application | 1x per day | Axiron | ||
Rectal | Testosterone | Suppository | 40 mg | 2–3x per day | Rektandron, Testosteron |
Injection (IM or SC) | Testosteronea | Aqueous suspension | 25, 50, or 100 mg/mL | 1x every 2–3 days | Andronaq, Sterotate, Virosterone |
Testosterone propionatea | Oil solution | 5, 10, 25, 50, or 100 mg/mL | 1x every 2–3 days | Testoviron | |
Testosterone isobutyratea | Aqueous suspension | 25 mg/mL | 1x every 1–2 weeks | Agovirin-Depot, Perandren M | |
Testosterone enanthate | Oil solution | 50, 100, 180, 200, or 250 mg/mL | 1x every 1–4 weeks | Delatestryl | |
Testosterone cypionate | Oil solution | 50, 100, 200, or 250 mg/mL | 1x every 1–4 weeks | Depo-Testosterone | |
Mixed testosterone esters | Oil solution | 100 or 250 mg/mL | 1x every 2–4 weeks | Sustanon 100, Sustanon 250 | |
Testosterone undecanoate | Oil solution | 750 or 1000 mg per injection | 1x every 10–14 weeks | Aveed, Nebido, Reandron | |
Implant | Testosterone | Pellet | 50, 75, 100, or 200 mg | 1x every 3–6 months | TestoImplant, Testopel |
Abbreviations: T = Testosterone. Footnotes: a = Discontinued or mostly discontinued. Notes: (1): This table does not include dosage information, which cannot necessarily be extrapolated from the provided information. (2): This table mostly does not include combination products. (3): Some of these formulations have been marketed previously but may no longer be available (e.g., transdermal testosterone scrotal patches, intramuscular testosterone suspension, intramuscular testosterone propionate). (4): The availability of pharmaceutical testosterone products differs by country (see Testosterone (medication) § Availability). Sources: [1][2][3][4][5][6][7][8][9][10][11][12][13][14] |
Template documentation
See also
- Testosterone (medication) § Available forms
- Pharmacokinetics of testosterone § Routes of administration
- Template:Available forms of estradiol
- Template:Available forms of progesterone
References
- ↑ Nieschlag E (September 2006). "Testosterone treatment comes of age: new options for hypogonadal men". Clin. Endocrinol. (Oxf). 65 (3): 275–81. doi:10.1111/j.1365-2265.2006.02618.x. PMID 16918944.
- ↑ Nieschlag E (January 2015). "Current topics in testosterone replacement of hypogonadal men". Best Pract. Res. Clin. Endocrinol. Metab. 29 (1): 77–90. doi:10.1016/j.beem.2014.09.008. PMID 25617174.
- ↑ Byrne M, Nieschlag E (May 2003). "Testosterone replacement therapy in male hypogonadism". J. Endocrinol. Invest. 26 (5): 481–9. doi:10.1007/bf03345206. PMID 12906378.
- ↑ M. Cappa; S. Cianfarani; L. Ghizzoni; S. Loche, M. Maghnie (10 December 2015). Advanced Therapies in Pediatric Endocrinology and Diabetology: Workshop, Rome, October 2014. Karger Medical and Scientific Publishers. pp. 68–. ISBN 978-3-318-05637-2.
- ↑ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Archived from the original on November 16, 2016. Retrieved November 16, 2016.
- ↑ Shlomo Melmed (1 January 2016). Williams Textbook of Endocrinology. Elsevier Health Sciences. pp. 760–769. ISBN 978-0-323-29738-7.
- ↑ Patrick Lenehan (12 June 2003). Anabolic Steroids. CRC Press. pp. 108–109. ISBN 978-0-415-28029-7.
- ↑ Becker, Kenneth L. (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 1116, 1119, 1152, 1182–1185, 1195–1197, 2146. ISBN 978-0-7817-1750-2. Archived from the original on May 5, 2017.
{{cite book}}
: Unknown parameter|name-list-format=
ignored (help) - ↑ Nieschlag, Eberhart; Behre, Hermann M. (6 December 2012). Testosterone: Action - Deficiency - Substitution. Springer Science & Business Media. pp. 1–, 9, 298, 309–331, 349–353, 366–367. ISBN 978-3-642-72185-4.
{{cite book}}
: Unknown parameter|name-list-format=
ignored (help) - ↑ Krishna; Usha R. And Shah (1996). Menopause. Orient Blackswan. pp. 70–. ISBN 978-81-250-0910-8.
- ↑ Janet Brotherton (1976). Sex Hormone Pharmacology. Academic Press. pp. 18–19, 331, 336. ISBN 978-0-12-137250-7.
- ↑ Barbara G. Wells; Joseph T. DiPiro; Terry L. Schwinghammer; Cecily V. DiPiro (22 August 2014). Pharmacotherapy Handbook, 9/E. McGraw-Hill Education. p. 288. ISBN 978-0-07-182129-2.
- ↑ Lauritzen, Christian (1988). "Natürliche und Synthetische Sexualhormone – Biologische Grundlagen und Behandlungsprinzipien" [Natural and Synthetic Sexual Hormones – Biological Basis and Medical Treatment Principles]. In Hermann P. G. Schneider; Christian Lauritzen; Eberhard Nieschlag (eds.). Grundlagen und Klinik der Menschlichen Fortpflanzung [Foundations and Clinic of Human Reproduction] (in German). Walter de Gruyter. pp. 229–306. ISBN 978-3110109689. OCLC 35483492.
{{cite book}}
: CS1 maint: unrecognized language (link) - ↑ Apotekens informationsavdelning (1964). Apotekens synonymregister över farmacevtiska specialiteter. Apotekens informationsavdelning.
Rektandron FERRING supp. 40 mg • individ. dos. • 10 st.